LAAO Versus NOAC in Patients with AF and PCI

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1386 participants.

Also called NCT05353140

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Not applicable
Enrolled
  • 1,386 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05353140
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05353140. Randomized; no masking; primary purpose prevention. Start 2022-09-01 (actual); primary completion 2028-09-20 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
LAAO Versus NOAC in Patients with AF and PCI
Intervention (Device)
The WATCHMAN/WATCHMAN FLX device
Intervention (Drug)
Rivaroxaban + Clopidogre
Intervention (Drug)
Aspirin + Clopidogrel
Lead sponsor
Xijing Hospital (class: other)

Record details

Record id
cardio:ct-nct05353140
Content hash
1dbebab1265f7345042a67f160b84e132b9bd53575c02be0a460fee446ed6060